Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.37 |
| ▸ | C3AR1 | Q16581 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | ALB | P02768 | 1/20 | 0.34 |
| ▸ | TLR2 | O60603 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.33 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.33 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16093019 | 0.91 | GLP1R (0.41) | GLP1RC3AR1ALBTLR2NOD1 | |
| SCHEMBL16093436 | 0.91 | GLP1R (0.38) | GLP1RC3AR1TSHRCASP1CASP7 | |
| SCHEMBL16093009 | 0.91 | GLP1R (0.38) | GLP1RC3AR1ALBTLR2NOD1 | |
| SCHEMBL25454947 | 0.88 | TLR2 (0.39) | GLP1RTSHRALBTLR2NOD1 | |
| SCHEMBL26425890 | 0.86 | GLP1R (0.48) | GLP1RC3AR1ALBTLR2SIRT2 | |
| SCHEMBL19069693 | 0.85 | GLP1R (0.41) | GLP1RC3AR1TSHRALBTLR2 | |
| SCHEMBL17424221 | 0.84 | GLP1R (0.49) | GLP1RC3AR1ALBTLR2NOD1 | |
| SCHEMBL25664162 | 0.82 | GLP1R (0.43) | GLP1RC3AR1ALBTLR2HSD17B10 | |
| SCHEMBL17903320 | 0.81 | GLP1R (0.41) | GLP1RC3AR1ALBSIRT5 | |
| SCHEMBL16093426 | 0.79 | HPGD (0.49) | C3AR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841249-B2 | Growth hormones with prolonged in-vivo efficacy | NOVO NORDISK A/S (DK) | 2014-09-23 | — | — | US | disclosed |